| Literature DB >> 22548090 |
J A Pralong1, A Cartier, O Vandenplas, M Labrecque.
Abstract
Background. More than 400 agents have been documented as causing occupational asthma (OA). The list of low-molecular-weight (LMW) agents that have been identified as potential causes of OA is constantly expanding, emphasizing the need to continually update our knowledge by reviewing the literature. Objective. The objective of this paper was to identify all new LMW agents causing occupational asthma reported during the period 2000-2010. Methods. A Medline search was performed using the keywords occupational asthma, new allergens, new causes, and low-molecular-weight agents. Results. We found 39 publications describing 41 new LMW causal agents, which belonged to the following categories: drugs (n = 12), wood dust (n = 11), chemicals (n = 8), metals (n = 4), biocides (n = 3), and miscellaneous (n = 3). The diagnosis of OA was confirmed through SIC for 35 of 41 agents, peak expiratory flow monitoring for three (3) agents, and the clinical history alone for three (3) agents. Immunological tests provided evidence supporting an IgE-mediated mechanism for eight (8) (20%) of the newly described agents. Conclusion. This paper highlights the importance of being alert to the occurrence of new LMW sensitizers, which can elicit OA. The immunological mechanism is explained by a type I hypersensitivity reaction in 20% of all newly described LMW agents.Entities:
Year: 2012 PMID: 22548090 PMCID: PMC3324913 DOI: 10.1155/2012/597306
Source DB: PubMed Journal: J Allergy (Cairo) ISSN: 1687-9783
New agents causing OA.
| Substances | Ref- | Workplace | No. of cases | Symptoms | Immunological tests | Functional tests | SIC | Remark | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| SPT | IgE | Increased NSBR | PEF | ||||||||
| Drugs | |||||||||||
|
| |||||||||||
| Vancomycin | [ | Pharmaceutical company | 1 | A, R | − | − | + | + | ND | NA | Intradermal test +/Histamine release test + |
| Colistin | [ | Pharmaceutical company | 1 | A, R | ND | − | − | ND | + | EAR | NSBR negative before SIC |
| 7-ACSA | [ | Pharmaceutical company | 2 | A (2/2), R (1/2) | + (1/2) | + (1/2) | + (2/2) | ND | + (2/2) | EAR (1/2) NS (1/2) | |
| Thiamphenicol | [ | Pharmaceutical company | 3 | A (3/3), R (3/3) | + (2/3) | + (2/3) | + (3/3) | ND | + (3/3) | EAR (2/3) LAR(1/3) | |
| Cefteram | [ | Pharmaceutical company | 2 | A | + (2/2) | + (2/2) | + (2/2) | ND | + (2/2) | EAR (2/2) | |
| 7-TACA | [ | Pharmaceutical company | 1 | A, R | ND | ND | − | ND | + | EAR | Increased nasal eosino count after SIC/NSBR negative before and after SIC |
| Thiamine | [ | Cereal manufacture | 2 | A (2/2) | ND | − (1/1) | + (1/1) | + (2/2) | + (2/2) | LAR (2/2) | Hypoxemia after SIC: pO2 45 mm Hg |
| Lasamide and precursors | [ | Pharmaceutical company | 3 | A (3/3), R (3/3) | ND | ND | + (2/3) | ND | + (3/3) | EAR (3/3) | NSBR negative before SIC in 1 subject |
| Aescin | [ | Pharmaceutical company | 1 | A, R | ND | ND | + | + | + | AAR | |
| Sevoflurane and isoflurane | [ | Hospital, anaesthetic staff | 2 | A (2/2), R (1/2), AR (1/2) | ND | ND | + (2/2) | + (1/2) | + (1/2) | LAR | |
| Mitoxantrone | [ | Hospital, oncology staff | 1 | A, R | ND | ND | + | ND | + | LAR | BAL: increase in neutrophils, lymphocytes and eosino after SIC |
| 5-ASA | [ | Pharmaceutical company | 1 | A | − | ND | + | ND | + | LAR | Increase in sputum eosino after SIC/Increase in eNO level after SIC |
|
| |||||||||||
| Total: 12 | 20 | A 20/R 13/D 0 | 5/9 | 5/10 | 16/19 | 5/6 | 18/19 | EAR 10/LAR 6/AAR 1/NS 1 | |||
|
| |||||||||||
| Wood dust | |||||||||||
|
| |||||||||||
| Tali | [ | Carpentry | 2 | A (2/2), R (2/2) | − (0/2) | − (0/2) | + (2/2) | + (2/2) | + (2/2) | LAR (1/2) DAR (1/2) | Increase in sputum eosino after SIC (2/2) |
| Jatoba | [ | Carpentry | 1 | A, R | − | − | + | + | + | EAR | Increase in sputum eosino after SIC |
| Chengal | [ | Carpentry | 1 | A, R | ND | ND | ND | + | + | EAR | |
| Falcata | [ | Wood furniture plant | 1 | A | ND | ND | ND | ND | + | EAR | Intradermal test +/Specific IgG + |
| Cedroarana | [ | Carpentry | 1 | A, R | + | + | − | ND | + | EAR | Nasal provocation test +/NSBR negative before and after SIC |
| Bethabara | [ | Railway platform | 1 | A | ND | ND | + | ND | + | LAR | Increase in sputum eosino after SIC |
| Angelim pedra | [ | Carpentry | 1 | A, R | + | + | + | ND | + | EAR | |
| Ipe | [ | Wood work | 1 | A | + | − | ND | ND | + | LAR | |
| Antiaris | [ | Door manufacture | 1 | A, R | + | + | + | ND | + | DAR | Conjunctival provocation test + |
| African cherry | [ | Carpentry | 1 | A | − | ND | + | ND | + | DAR | |
| Sapele | [ | Carpentry | 1 | A, R, D | − | + | ND | ND | ND | NA | |
|
| |||||||||||
| Total: 11 | 12 | A 12/R 8/D1 | 4/9 | 4/8 | 7/8 | 4/4 | 11/11 | EAR 5/LAR 3/DAR 3 | |||
|
| |||||||||||
| Metals | |||||||||||
|
| |||||||||||
| Manganese | [ | Welding | 1 | A | − | ND | + | + | + | EAR | Increase in sputum eosino and basophils after SIC |
| Rhodium | [ | Electroplating plant | 1 | A, R | + | − | + | ND | + | EAR | |
| Stellite | [ | Machine manufacture | 1 | A | − | ND | + | + | + | DAR | |
| Iron (fumes) | [ | Welding | 3 | A (3/3) | ND | ND | + (3/3) | + (1/3) | + (3/3) | DAR (1/3) AAR (2/3) | Increase in sputum neutrophils after SIC (3/3) |
|
| |||||||||||
| Total: 4 | 6 | A 6/R 1/D 0 | 1/3 | 0/1 | 6/6 | 3/5 | 6/6 | EAR 2/DAR 2/AAR 2 | |||
|
| |||||||||||
| Chemicals | |||||||||||
|
| |||||||||||
| Uronium salts | [ | Peptides synthesis lab | 1 | A, R | + | − | + | ND | + | EAR | Increase in sputum eosino after SIC |
| Dodecanedioic acid gel flux | [ | Electronics company | 1 | A, R | ND | ND | + | + | + | EAR | Low eNO level before SIC |
| Adipic acid flux | [ | Soldering | 1 | A | ND | ND | + | + | + | LAR | |
| 3-amino-5-mercapto-1,2,4-triazole | [ | Production of herbicides | 6 | A (6/6), R (6/6) | ND | ND | + (6/6) | + (3/4) | ND | NA | |
| Sodium disulphite | [ | Lobster fishing | 1 | A | − | − | + | + | + | EAR | |
| Tetramethrin | [ | Insect extermination firm | 1 | A | − | ND | + | ND | + | DAR | |
| Eugenol | [ | Hairdressing salon | 1 | A, R, D | − | ND | + | ND | + | LAR | Increase in sputum eosino and lymphocytes after SIC |
| Artificial flavour | [ | Popcorn popping company | 3 | A | ND | ND | ND | ND | ND | NA | |
|
| |||||||||||
| Total: 8 | 15 | A 15/R 9/D1 | 1/4 | 0/2 | 12/12 | 6/7 | 6/6 | EAR 3/LAR 2/DAR 1 | |||
|
| |||||||||||
| Biocides | |||||||||||
|
| |||||||||||
| Nitrogen trichloride | [ | Swimming-pool | 3 | A | ND | ND | + (1/3) | + (2/3) | + (3/3) | EAR (2/3) DAR (1/3) | NSBR negative before SIC in 1 subject and negative before and after SIC in another subject |
| PA-HP | [ | Endoscopic unit | 2 | A (2/2), R (2/2) | ND | ND | + (2/2) | + (1/1) | + (1/1) | LAR | Increase in sputum eosino after SIC (1/1) |
| Ortho-phthalaldehyde | [ | Endoscopic unit | 1 | A, D | ND | ND | ND | ND | ND | NA | |
|
| |||||||||||
| Total: 3 | 6 | A 6/R 2/D1 | ND | ND | 3/5 | 3/4 | 4/4 | EAR 2/LAR 1/DAR 1 | |||
|
| |||||||||||
| Miscellaneous | |||||||||||
|
| |||||||||||
| Fluazinam | [ | Fungicides manufacture | 1 | A | ND | ND | + | + | + | LAR | |
| Chlorothalonil | [ | Fungicides manufacture | 1 | A | ND | ND | − | + | + | LAR | NSBR negative before SIC and borderline after SIC |
| Chlorendic anhydride | [ | Mechanic work | 1 | A, D | + | + | ND | + | ND | NA | |
|
| |||||||||||
| Total: 3 | 3 | A 3/R 0/D1 | 1/1 | 1/1 | 1/2 | 3/3 | 2/2 | LAR 2 | |||
|
| |||||||||||
| Total: 41 | 62 | A 62/R 33/D 4 | 12/26 | 10/22 | 45/52 | 24/29 | 47/48 | EAR 22/LAR 14/DAR 7/AAR 3/NS 1/47 | |||
Legend: A: asthma, R: rhinitis, D: dermatitis; U: urticaria; AR: anaphylactic reaction; PEF: peak expiratory flow, SIC: specific inhalation challenge SPT: skin prick test, IgE: specific immunoglobulin E, NSBR: nonspecific bronchial responsiveness EARs: early asthmatic reaction, LAR: late asthmatic reaction, DAR: dual asthmatic reaction, AAR: atypical asthmatic reaction ND: not done, NA: not available, NS: not specified, eosino: eosinophils, 7-ACSA: 7-aminocephalosporanic acid, 7-TACA: 7-amino-3-thiomethyl-3-cephalosporanic acid, 5-ASA: 5-aminosalicylic acid, PA-PH: peracetic acid-hydrogen peroxyde mixture, BAL: bronchoalveolar lavage, eNO: exhaled nitric oxyde, IgG: immunoglobulin G.